Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.

CONCLUSION: The investigational QIV was immunogenic with an acceptable safety profile in children 6 months to 8 years of age.
CLINICAL TRIAL REGISTRATION: NCT03336593.
PMID: 31862195 [PubMed - as supplied by publisher]

Source: Vaccine - December 16, 2019 Category: Allergy & Immunology Authors: Dhamayanti M, Tarigan R, Fadlyana E, Prasetyo D, Amalia N, Rusmil VK, Sari RM, Bachtiar NS, Rusmil K, Kartasasmita CB Tags: Vaccine Source Type: research